Back to search results

Navigational Devices for Urologic Cancer Surgery

This study is looking at how two navigation systems, 3D Slicer and Siemens Monaco, can help surgeons remove lymph nodes (small glands that are part of your immune system) in people with urologic cancer. The goal is to make these surgeries, called lymphadenectomies, simpler and more accurate by giving surgeons better views and helping them find diseased lymph nodes more easily. This could lead to better outcomes for patients, fewer complications, and improved surgical performance. The study aims to see if these navigation systems can increase efficiency and reduce problems associated with removing affected lymph nodes. You may be able to join if you are 18 or older and have a confirmed or suspected urologic cancer that requires a surgical biopsy. The study will measure how many patients successfully complete their intended surgery using these devices.

Study design
This interventional study plans to enroll 20 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for one month, up to 45 days after registration, to assess the completion of the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05132283

Urologic Lymphadenectomy in AMIGO

Recruiting
NAAges 18+InterventionalDiagnostic
Brigham and Women's Hospital
~20 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:3D SlicerMonaco

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Patients Completing Intended Procedure (Feasibility)
Measured over One month, up to 45 days after registration

Conditions

Urologic Cancer
Lymph Node Metastasis

Explore related trials

Bladder CarcinomaKidney CarcinomaMalignant Testicular NeoplasmMalignant Urinary Tract NeoplasmPenile CarcinomaProstate CarcinomaUrethral Carcinoma

NCT05132283

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Brigham and Women's Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Matthew Mossanen, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital

Who to contact

Matthew Mossanen, MD
[email protected]
(617) 732-6384
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management
Subjects aged ≥ 18 years. Selected patients must have a confirmed or suspected diagnosis of disease in urologic regions of interest, with scheduled confirmatory surgical biopsy.
Subjects must have had a CT, PET or MR examination of acceptable quality at Brigham and Women's Hospital within the prior month.
Subjects must also be scheduled to undergo lymphadenectomy for a urologic cancer within the following urologic regions of interest: Bladder, Prostate, Testicular, Kidney, Urethral, and Penile.
Subjects must also be scheduled to undergo a laparoscopic lymphadenectomy within the AMIGO OR

Exclusion

Severely impaired renal function with an EGFR \< 30 mL/min/body surface area
Evidence of any significant, uncontrolled comorbid condition that could affect compliance with the protocol or interpretation of the results, which is to be judged at the discretion of the PI
History of hypersensitivity or other contraindication to contrast media
Contraindication to general anesthesia
Pregnancy

What this trial measures

  • Proportion of Patients Completing Intended Procedure (Feasibility)One month, up to 45 days after registration

    The Slicer-Monaco prototype navigation platform will be used to resect enlarged and/or fluorodeoxyglucose avid lymph nodes. The successful navigational use of this platform will be considered as completed. The proportion of patients completing this intended procedure will be reported.